Relationships of Executive Functions, Severity of Psychiatric Symptoms With Response to Therapy

University of Bojnord

This study was conducted to investigate the moderating role of executive functions in the relationship between the severity of psychiatric symptoms and response to therapy. The statistical population of this study was all outpatients with anxiety disorders and depression who referred to psychiatric clinics.

Study Overview

• Status: Completed
• Conditions: Patient Acceptance of Health Care
• Intervention / Treatment: Other: DRUG

Detailed Description

This study was conducted to investigate the moderating role of executive functions in the relationship between the severity of psychiatric symptoms and response to drug therapy in depressed and anxious patients. The statistical population of this study was all outpatients with anxiety disorders and depression who referred to psychiatric clinics. 164 participants completed Outcome Questionnaire, Brief Symptom Inventory, and Behavior Rating Inventory of Executive Function (BRIEF).

• Study Type: Observational
• Enrollment (Actual): 164

Contacts and Locations

Study Locations

• Iran, Islamic Republic of
  • North Khorsan
    • Bojnourd, North Khorsan, Iran, Islamic Republic of
      • Malahat Amani

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (Adult)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The statistical population included all adult outpatients with anxiety and depression disorders who referred to psychiatric offices in Bojnord city Sample was selected among the clients of psychiatric offices who received the diagnosis of anxiety and depression disorders and volunteer to participate in the study were sample (n=164)

Description

Inclusion Criteria:

receiving a diagnosis of anxiety and depression disorders, age over 18 years, and taking drug medication prescribed by psychiatrists for at least one month.-

Exclusion Criteria:

• having psychotic disorders, age under 18 years and absence from treatment.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Outcome questionnaire	This questionnaire was designed to assess response to treatment. This questionnaire has the dimension of mental distress or signs of distress, interpersonal relationships, and social role. This 45-item questionnaire is answered on a 5-point Likert scale ranging 0 to 4 (not at all to extremely).Scores range from 0 to180. higher scores mean a worse outcome.	ONE WEEK
Brief Symptom Inventory	This inventory measures the symptoms of psycho-somatization, obsessive-compulsive, interpersonal sensitivity, paranoid thoughts, depression, psychosis, general anxiety, hostility and anxiety. It was answered to questions based on the 5-point Likert scale ranging from 0 to 4 (not at all to perfectly). This questionnaire is 53 items. Scores range from 0 to 212.range of score are higher scores mean a worse outcome and mental health problems.	ONE WEEK
Behavior Rating Inventory of Executive Function	This questionnaire is used to measure the executive functions of adults aged 18 to 90 from their daily performance in the natural environment. It has 75 items that measure factors including response inhibition, shifting, emotional control, self-monitoring, initiation, working memory, planning, material organization, and task monitoring. It was answered to questions based on the 3-point Likert scale ranging from 0 to 2 (not at all to extremely). the scores range 0 to 150. High score is indicator of weak executive functions.	ONE WEEK

Collaborators and Investigators

• Sponsor: Malahat Amani
• Investigators: Principal Investigator: Malahat amani, ph.d, University of Bojnord

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2019
• Primary Completion (Actual): February 1, 2019
• Study Completion (Actual): March 1, 2019

Study Registration Dates

• First Submitted: October 20, 2020
• First Submitted That Met QC Criteria: October 20, 2020
• First Posted (Actual): October 26, 2020

Study Record Updates

• Last Update Posted (Actual): October 28, 2020
• Last Update Submitted That Met QC Criteria: October 26, 2020
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: 13180899

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No